Just thought I post this news on another co. Adlers is associated with. There appears to be real science behind Apinol. PRLN is weak these days, and I have to believe something has occurred within PRLN that is negative. Please, someone give me a fair explaination of what the hell is going on. I've read this thread for a long time now, so I know it's past. I need something concrete to reassure me the story has changed fundamentally. Anyone know their burn rate? Is a May role-out of Androvir still scheduled? Have obstacles arisen since Babish's departure, or where obstacles the reason for his departure? Any responses the provide any whisper of insight into this co are appreciated. I'm not looking for insider info., just a fair assessment of what the hell is going on. here's that Alberts news. Anyone have any thoughts on Inflazyme. pamileti@lynx.neu.edu
Thursday January 9 11:50 AM EDT
Inflazyme Pharmaceuticals Ltd. Appoints Alfred Alberts To Its Board
Of Directors
VANCOUVER, Jan. 9 /CNW-PRN/ - Inflazyme Pharmaceuticals Ltd., VSE:IZP,
NASDAQ-BB:IZYPF) today announced the appointment of Mr. Alfred W. Alberts to its
Board of Directors. Mr. Alberts has had a distinguished career, which included seven
years as a chemist at the National Institutes of Health (NIH), and twenty years in senior
positions at Merck Research Laboratories. In June 1995 he retired as Vice President,
New Products Development, Biochemistry and Natural Products Discovery, at Merck
Research Laboratories, Rahway, NJ. During his Merck tenure, Mr. Alberts directed
research programs in atherosclerosis, diabetes, obesity and inflammation, and was
responsible for the discovery and development of Lovastatin and Simvastatin, cholesterol
lowering agents used in treating cardiovascular conditions. ``Alfred brings enormous
experience, gathered from years of high level research and management both in
government service and the private sector, to Inflazyme. Clearly, Inflazyme's
management team will be strengthened by his stature in the pharmaceutical industry and
his breadth of knowledge in drug innovation,'' said Inflazyme's President and CEO, Dr.
Hassan Salari. Inflazyme is an emerging pharmaceutical company focused on the
discovery and development of therapeutic agents for diseases with a major inflammatory
component. Inflazyme's lead compound, Apanol, appears to possess properties that may
make it an orally effective agent for the treatment of asthma. Other lead indications for
Inflazyme's developing technologies include allergy, arthritis and psoriasis.
The statements made in this press release may contain certain forward-looking statements. Actual events or results may differ
from the Company's expectations. In addition to the matters described in this press release, future actions by the Food and
Drug Administration or equivalent regulatory authorities in foreign countries, results of pending or future clinical trials, as well
as risk factors from time to time in the Company's SEC reports, may affect the actual results achieved by the Company. The
Vancouver Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Exemption from registration pursuant to Rule l2g3-2(b), Reg. No.82-2317.
SOURCE: Inflazyme Pharmaceuticals Ltd. |
